CSS
ORIC icon

Cubist Systematic Strategies’s Oric Pharmaceuticals ORIC Stock Holding History

Cubist Systematic Strategies’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,309
Closed -$36K – 4083
2023
Q1 		$36K Buy
6,309
+836
+15% +$4.37K ﹤0.01% 3610
2022
Q4 		$32.2K Sell
5,473
-8,090
-60% -$27.3K ﹤0.01% 3957
2022
Q3 		$43K Buy
13,563
+147
+1% +$588 ﹤0.01% 4150
2022
Q2 		$60K Sell
13,416
-62,183
-82% -$248K ﹤0.01% 4067
2022
Q1 		$404K Buy
+75,599
New +$681K ﹤0.01% 2663
2021
Q4 		– Sell
-2,145
Closed -$45K – 3581
2021
Q3 		$45K Sell
2,145
-8,879
-81% -$180K ﹤0.01% 2844
2021
Q2 		$195K Buy
11,024
+9,674
+717% +$212K ﹤0.01% 2574
2021
Q1 		$33K Buy
+1,350
New +$42.7K ﹤0.01% 2752
2020
Q3 		– Sell
-10,598
Closed -$357K – 2587
2020
Q2 		$357K Buy
+10,598
New +$338K 0.01% 1768

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cubist Systematic Strategies's ORIC Position: Q2 2023 in Review

Cubist Systematic Strategies sold out of Oric Pharmaceuticals (ORIC) in Q2 2023, closing a stake of 6,309 shares — an estimated $36K sold.

Cubist Systematic Strategies first reported a position in ORIC in Q2 2020 and held it in 9 quarters. The position peaked at $404K in Q1 2022. 83 funds tracked by Wall St. Rank hold ORIC as of Q2 2023.

  • Cubist Systematic Strategies reported no remaining Oric Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 6,309 Oric Pharmaceuticals shares in Q2 2023, an estimated $36K.
  • Cubist Systematic Strategies first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 9 quarters.
  • Cubist Systematic Strategies's Oric Pharmaceuticals position peaked at $404K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2023.

Based on Cubist Systematic Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.